Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

ment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and patients who have failed to respond to previous therapy.

Important Safety Information about PEGASYS

PEGASYS, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).

Alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

Use with Ribavirin. Ribavirin, including COPEGUS(R), may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with ribavirin therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

PEGASYS is contraindicated in patients with hypersensitivity to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during tre
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 6, 2015 Mauna Kea ... multidisciplinary confocal laser endomicroscopy platform, announced today it ... Ministry of Health, Labor and Welfare (MHLW) ... the AQ-Flex 19 miniprobe.   Used ... miniprobe is comprised of a fiber-optic microscope that ...
(Date:7/6/2015)... 6, 2015   BioClinica®, Inc ., a ... announced that it has acquired a leading global ... Inc. (Medici).  The acquisition includes affiliates MediciGlobal ... also provides a lost-to-follow-up patient locate service ( ... with Medici, BioClinica will offer pharmaceutical ...
(Date:7/6/2015)... DUBLIN, Ohio , July 6, 2015 ... of The Harvard Drug Group (THDG). A distributor of generic ... and alternate care customers, THDG was owned by Court ... all-cash transaction using existing cash and new debt.  ... , The Harvard Drug Group had revenues of approximately ...
Breaking Medicine Technology:Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 3BioClinica Acquires MediciGroup 2BioClinica Acquires MediciGroup 3Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 2Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 3
... May 10th, 2007 - Antisense,Pharma, a German biopharmaceutical ... announced, that data from the,Phase IIb-study with AP ... 43rd Annual Meeting of the American Society of,Clinical ... Illinois,U.S.A, from June 1st - 5th. , In ...
... NICE Appraisal Committee concludes that alteplase is clinically,and ... 2007 – A new clinical appraisal,published by the ... the UK has recommended the use of alteplase,for ... based on,its clinical and cost effectiveness compared with ...
Cached Medicine Technology:2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 22007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 2Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 4Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 5
(Date:7/6/2015)... ... , ... MD Now, the leading and fastest-growing urgent care provider in Florida, ... will serve residents and visitors in the Cutler Bay area, giving them convenient access ... location, the new facility will be the fourth to serve Miami-Dade County. Located at ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... received nearly $400,000 in grant funds to support a three-year effort to reduce ... The work will be conducted in partnership with the Morehouse School of Medicine’s ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... Randstad Technologies selected Aspect Software Unified IP contact center solution hosted by Promero. ... Aspect Unified IP as its future call center platform. , Promero will ...
(Date:7/6/2015)... , ... July 06, 2015 , ... Thanks to donations ... and Hospice received the Music & Memory Certification for hospice patients and adult day ... of music not only to patients but also to their families and volunteers. Music ...
(Date:7/5/2015)... ... 2015 , ... City Sports, the Boston-based specialty sporting goods retailer, has renewed ... first-time triathletes this summer with ethos, the owner and operator of the Boston Triathlon. ... 6:00 p.m. at the North End Greenway. The event will help new triathletes prepare ...
Breaking Medicine News(10 mins):Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 3Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 4Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 3
... to DNA mutation is a driving force of adaptation ... disease. However, the mechanisms governing DNA mutation rate ... online today in Genome Research ( http://www.genome.org ... influence mutation rate, shedding light on mechanisms involved in ...
... May 24, 2010 Neuralstem, Inc. (NYSE ... human clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or ... The company announced that, after reviewing the safety data from ... has approved moving to the next cohort and transplantation of ...
... ... IT GRC Program, , ... Austin, Texas (PRWEB) May 24, 2010 -- TruArx®, the leader in cost-effective, easy-to-implement ... webcast this week on identifying and managing compliance against all data security and privacy ...
... ,too much too soon, but study finds no impact ... -- Some American parents are choosing to space out ... infants are getting too many shots too soon, potentially ... has been especially persistent when it comes to autism, ...
... , ... Company offers affordable expert facilitation, project management support and peer-to-peer learning opportunities to ... ... the American Academy of Family Physicians, today announced a new service offering aimed ...
... regarding environmental factors influencing the risk of Alzheimer,s disease ... In particular, the roles of smoking and alcohol consumption ... in the Journal of Alzheimer,s Disease suggests ... of Alzheimer,s disease, particularly in women who do not ...
Cached Medicine News:Health News:New research indicates that DNA sequence itself influences mutation rate 2Health News:TruArx to Host Webcast Highlighting Successful IT GRC Program Management 2Health News:No Benefit Seen in Delaying Infant Vaccinations 2Health News:No Benefit Seen in Delaying Infant Vaccinations 3Health News:TransforMED Launches New Service Offering to Accelerate Medical Home Adoption in Small Practices 2Health News:TransforMED Launches New Service Offering to Accelerate Medical Home Adoption in Small Practices 3Health News:TransforMED Launches New Service Offering to Accelerate Medical Home Adoption in Small Practices 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: